Our findings suggest that GM1 treatment in both KO and HT mice, despite the severity of the disease in the KO mice, can alleviate motor and short‐term spatial memory dysfunctions and may lead to the development of a clinically relevant treatment for GM3 synthase deficiency. The gene discussed is ST3GAL5; the disease is hyperinsulinemic hypoglycemia, familial, 4.